Glycomics and Glycan Bioengineering Research Center (GGBRC), College of Food Science and Technology, Nanjing Agricultural University, China.
Glycomics and Glycan Bioengineering Research Center (GGBRC), College of Food Science and Technology, Nanjing Agricultural University, China.
Biochim Biophys Acta Proteins Proteom. 2020 Feb;1868(2):140301. doi: 10.1016/j.bbapap.2019.140301. Epub 2019 Oct 31.
Heparin is a naturally occurring glycosaminoglycan isolated from animal tissues and is medically used as an anticoagulant drug. Adulteration attempts of isolated heparin with chondroitin sulfate in the past resulted in great safety concerns. Also, increasing demands on batch-to-batch homogeneity for better evaluation and control of its pharmacodynamic and pharmacokinetic properties kindled the development of synthetic routes for the production of heparin and its derivatives. The discovery of enzymes involved in glycosaminoglycan biosynthesis and their application in chemoenzymatic synthesis makes it feasible to generate low molecular weight heparins (LMWHs) and ultra-low molecular weight heparins (ULMWHs). Understanding the scope and limitations of these enzymes currently used in the production of synthetic heparins will help to achieve more defined heparins with controlled medicative properties. Here, we summarized the recent advances in the chemoenzymatic synthesis of LMW/ULMW heparins.
肝素是一种从动物组织中分离出来的天然糖胺聚糖,在医学上用作抗凝药物。过去,肝素与硫酸软骨素的分离掺假尝试引起了极大的安全关注。此外,为了更好地评估和控制其药效学和药代动力学特性,对批次间均一性的需求不断增加,促使人们开发了用于生产肝素及其衍生物的合成途径。参与糖胺聚糖生物合成的酶的发现及其在化学酶合成中的应用,使得生成低分子量肝素 (LMWHs) 和超低分子量肝素 (ULMWHs) 成为可能。了解目前用于合成肝素生产中使用的这些酶的范围和局限性,将有助于实现具有可控药用特性的更明确的肝素。在这里,我们总结了 LMW/ULMW 肝素化学酶合成的最新进展。